Table 5 Univariate analysis of the impact of serine/glycine-related protein expression in papillary thyroid carcinoma on disease-free and overall survival by the log-rank test
Parameter | Number of patientsa/recurrence/death | Disease-free survival | Overall survival | ||
|---|---|---|---|---|---|
Mean survival (95Â % CI) months | p value | Mean survival (95Â % CI) months | p value | ||
PHGDH in tumor | 0.790 | Â | 0.806 | ||
 Negative | 126/6/6 | 105 (101–108) |  | 106 (103–109) |  |
 Positive | 218/12/12 | 106 (104–109) |  | 107 (105–110) |  |
PSAT1 in tumor | 0.159 | Â | 0.231 | ||
 Negative | 280/17/13 | 106 (103–109) |  | 108 (106–110) |  |
 Positive | 64/1/5 | 108 (105–111) |  | 103 (97–108) |  |
PSPH in tumor | 0.606 | Â | 0.221 | ||
 Negative | 300/15/14 | 107 (105–109) |  | 108 (106–110) |  |
 Positive | 44/3/4 | 103 (96–110) |  | 103 (96–109) |  |
SHMT1 in tumor | 0.498 | Â | 0.248 | ||
 Negative | 236/11/10 | 107 (105–110) |  | 108 (106–110) |  |
 Positive | 108/7/8 | 104 (100–109) |  | 105 (101–109) |  |
SHMT1 in stroma | 0.655 | Â | 0.684 | ||
 Negative | 212/12/10 | 106 (103–109) |  | 108 (106–110) |  |
 Positive | 132/6/8 | 107 (104–111) |  | 107 (103–110) |  |
GLDC in tumor | 0.516 | Â | 0.059 | ||
 Negative | 285/14/12 | 107 (105–109) |  | 108 (106–110) |  |
 Positive | 59/4/6 | 104 (97–110) |  | 103 (97–109) |  |